Who are the top shareholders of the Broach?

The top shareholder of Broach is Jaykumar Narendra Vyas, holding 63.75% of the shares, with no pledged promoter holdings. The highest public shareholder is Kaushik Bhupatrai Joshi at 5.27%, while individual investors collectively own 33.77%.

The top shareholders of Broach include the promoters, with Jaykumar Narendra Vyas holding the largest share at 63.75%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Kaushik Bhupatrai Joshi, who owns 5.27%. Additionally, individual investors collectively hold 33.77% of the shares.

What does Broach do?

Broach Lifecare Hospital Ltd, a micro-cap company incorporated in 2023, operates in the hospital industry after acquiring Dr. Jaykumar Narendra Vyas's Heart Hospital and Dr. Vyas Hospital. It has a market cap of Rs 14 Cr, with key metrics including a P/E of 13.00 and a return on equity of 13.01%.

Overview:<BR>Broach Lifecare Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 2023 and underwent a status change when it acquired the proprietorship concern of Dr. Jaykumar Narendra Vyas, which includes Dr. Vyas's Heart Hospital and Dr. Vyas Hospital, through a Business Transfer Agreement dated July 17, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 14 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.01<BR>Return on Equity: 13.01%<BR>Price-to-Book: 2.26<BR><BR>Contact Details:<BR>Registrar Address: Not available.

When is the next results date for Broach?

No Upcoming Board Meetings

Has Broach declared dividend?

No Dividend History Available

Who are the peers of the Broach?

Broach's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Key insights show excellent management risk at most peers, varied growth rates, and Krishna Institute leading with an 85.24% 1-year return.

Peers: The peers of Broach are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Rainbow Child., Dr Agarwal's Hea, and Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu., Rainbow Child., Dr Agarwal's Hea, and Jupiter Life Lin, while Average management risk is found at Fortis Health. and Aster DM Health. Below Average growth is noted at Aster DM Health., Krishna Institu., and Rainbow Child., while Good growth is seen at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Jupiter Life Lin. Excellent capital structure is present at Max Healthcare, Global Health, Krishna Institu., and Jupiter Life Lin, while Average capital structure is found at Apollo Hospitals and Fortis Health., and Below Average capital structure is noted at Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu. at 85.24%, while the lowest is Dr Agarwal's Hea with no available data. Broach's 1-year return is not available for comparison. Additionally, Aster DM Health. and Dr Agarwal's Hea have negative six-month returns.

How big is Broach Lifecare?

As of 24th July, Broach Lifecare Hospital Ltd has a market capitalization of 12.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 5.47 Cr and Total Assets of 5.72 Cr; however, recent financial data for Net Sales and Net Profit is unavailable.

As of 24th July, <BR><BR>Market Cap: Broach Lifecare Hospital Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company. <BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters. <BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 5.47 Cr and Total Assets totaling 5.72 Cr.

How has been the historical performance of Broach Lifecare?

Broach Lifecare's historical performance from March 2024 to March 2025 shows increased net sales and shareholder equity, but a decline in profitability metrics and negative cash flow from investing activities indicate financial challenges.

Answer:<BR>The historical performance of Broach Lifecare shows a mixed trend in financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Broach Lifecare reported net sales of 3.18 Cr, an increase from 2.61 Cr in the previous year. Total operating income also rose to 3.18 Cr from 2.61 Cr, while total expenditure increased to 2.35 Cr from 1.58 Cr. Operating profit (PBDIT) decreased to 0.88 Cr from 1.03 Cr, leading to a decline in profit before tax to 0.72 Cr from 0.93 Cr. Consequently, profit after tax fell to 0.54 Cr from 0.70 Cr. The earnings per share (EPS) dropped to 0.89 from 1.57, reflecting a decrease in profitability. On the balance sheet, shareholder's funds grew to 9.36 Cr from 5.47 Cr, and total liabilities increased to 10.92 Cr from 5.72 Cr. The company reported a cash flow from financing activities of 4.00 Cr, consistent with the previous year, while cash flow from investing activities showed a negative trend at -3.00 Cr, worsening from -1.00 Cr. Overall, while Broach Lifecare experienced growth in sales and shareholder equity, profitability metrics and cash flow from operations indicate challenges in maintaining financial health.

Is Broach Lifecare overvalued or undervalued?

As of November 17, 2025, Broach Lifecare is considered very attractive and undervalued with a PE ratio of 19.11, significantly lower than its peers, indicating strong growth potential despite a year-to-date stock performance lagging behind the Sensex.

As of 17 November 2025, Broach Lifecare's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 19.11, an EV to EBIT ratio of 9.65, and a Price to Book Value of 1.07. These metrics suggest that Broach Lifecare is trading at a lower valuation compared to its peers in the healthcare sector.<BR><BR>In comparison to its peers, Broach Lifecare's PE ratio of 19.11 is notably lower than Apollo Hospitals at 64.41 and Narayana Hrudaya at 48.72, both of which are considered expensive. Additionally, the PEG ratio for Broach Lifecare stands at 0.00, indicating strong growth potential relative to its price, especially when contrasted with peers like Max Healthcare, which has a PEG ratio of 2.30. Despite the company's recent stock performance lagging behind the Sensex, with a year-to-date return of -21.3% compared to the Sensex's 8.72%, the underlying valuation metrics suggest that Broach Lifecare presents a compelling investment opportunity at its current price of 17.00.

Which are the latest news on Broach Lifecare?

Why is Broach Lifecare falling/rising?

As of 03-Dec, Broach Lifecare Hospital Ltd's stock price is currently at 15.50, reflecting a daily increase of 2.65%. Despite this short-term rise, the stock has experienced significant declines over the year and is trading below all its moving averages, indicating ongoing challenges.

As of 03-Dec, Broach Lifecare Hospital Ltd's stock price is rising, currently at 15.50, with a change of 0.4 (2.65%) upwards. This increase can be attributed to the stock outperforming its sector by 3.55% today, indicating a relative strength compared to its peers. However, it is important to note that despite this daily rise, the stock has shown a significant decline over longer periods, with a year-to-date drop of 28.24% and a one-year decline of 37.98%. <BR><BR>Additionally, the stock has been experiencing erratic trading, having not traded on 3 out of the last 20 days, which may contribute to volatility in its price movements. The stock is currently trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), suggesting a longer-term bearish trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume on December 2nd falling by 58.33% compared to the 5-day average. <BR><BR>Overall, while the stock is experiencing a rise today, the broader context indicates ongoing challenges that have led to significant declines in its value over time.